Sugi Predict

Sugi Predict / Compounds / SCHEMBL1779667

SCHEMBL1779667

SCHEMBL1779667

O=S(=O)(CCBr)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSIP1 O75475 1/20 0.56
▸ HSD11B1 P28845 6/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ HTR6 P50406 1/20 0.46
▸ KEAP1 Q14145 1/20 0.46
▸ NFE2L2 Q16236 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ MAPT P10636 1/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44
▸ HDAC11 Q96DB2 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ HDAC9 Q9UKV0 1/20 0.44
▸ HDAC5 Q9UQL6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742560 0.86 PSIP1 (0.52) PSIP1HSD11B1L3MBTL1HTR6KEAP1
SCHEMBL777601 0.85 PSIP1 (0.67) PSIP1HSD11B1L3MBTL1HTR6KEAP1
SCHEMBL6096865 0.85 KEAP1 (0.54) PSIP1HSD11B1L3MBTL1KEAP1NFE2L2
SCHEMBL7744005 0.83 HDAC1 (0.56) PSIP1HSD11B1L3MBTL1KEAP1NFE2L2
SCHEMBL1022429 0.80 PSIP1 (0.61) PSIP1HSD11B1HTR6MAPTPOLB
SCHEMBL576918 0.80 KEAP1 (0.63) PSIP1HSD11B1L3MBTL1HTR6KEAP1
SCHEMBL10629823 0.80 PSIP1 (0.61) PSIP1HSD11B1L3MBTL1HTR6KEAP1
SCHEMBL19127744 0.79 PLCG1 (0.64) HSD11B1L3MBTL1MEN1KMT2APOLB
SCHEMBL10626503 0.78 HDAC1 (0.65) PSIP1HSD11B1L3MBTL1HTR6KEAP1
SCHEMBL2454944 0.78 PSIP1 (0.58) PSIP1HSD11B1L3MBTL1HTR6KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860636-B1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE INC (US) 2026-01-28 — — EP disclosed
US-12428415-B2 Matriptase 2 inhibitors and uses thereof DISC MEDICINE, INC. (US) 2025-09-30 — — US disclosed
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. 2023-02-09 — — US disclosed
EP-3860636-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF Disc Medicine, Inc. (US) 2021-08-11 — — EP disclosed
CN-112996529-A Matriptase 2 inhibitor and application thereof 迪斯克医药公司 2021-06-18 — — CN disclosed
WO-2020072580-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. (US) 2020-04-09 — — WO disclosed
CN-108779096-A A kind of fluorine-substituted cyclopropylamine class compound and preparation method thereof, pharmaceutical composition and purposes 中国科学院上海药物研究所 2018-11-09 — — CN disclosed
CN-108697811-A Inhibition of ataxia telangiectasia and Rad 3-related protein (ATR) 梅里麦克制药股份有限公司 2018-10-23 — — CN disclosed
CN-107200706-A Cyclopropylamine class compound of one class fluorine substitution and preparation method thereof, pharmaceutical composition and purposes 中国科学院上海药物研究所 2017-09-26 — — CN disclosed
CN-101795688-B Application of 4- (pyrrolidine-1-yl) quinoline compound in preparation of medicine for killing clinically latent microorganisms HELPERBY THERAPEUTICS LTD 2015-05-20 — — CN disclosed
US-20090247547-A1 HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B NOVARTIS AG 2009-10-01 — — US disclosed
US-20090247547-A1 HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B NOVARTIS AG 2009-10-01 — — US disclosed
US-20090247547-A1 HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B NOVARTIS AG 2009-10-01 — — US disclosed
CN-101316591-A Quinolines and their therapeutic use ARGENTA DISCOVERY LTD (GB) 2008-12-03 — — CN disclosed
WO-2008096128-A1 OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES 2 ARGENTA DISCOVERY LTD (GB) 2008-08-14 — — WO disclosed
US-5864039-A THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1999-01-26 — — US disclosed
EP-0873990-A1 BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-10-28 — — EP disclosed
EP-0282133-B1 1-ALKYL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1993-07-28 — — EP disclosed
US-4943580-A ANTIALLERGENS JANSSEN PHARMACEUTICA N.V. (BE) 1990-07-24 — — US disclosed
EP-0282133-A2 1-alkyl substituted benzimidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1988-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428415-B2 Matriptase 2 inhibitors and uses thereof MMP7, MATR3, SPINT2 PSIP1 2027/4885HSD11B1 2151/4885L3MBTL1 1147/4885
US-20090247547-A1 HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B HDAC1, HDAC11, HDAC3 PSIP1 3542/4885HSD11B1 231/4885L3MBTL1 1363/4885
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF MMP7, MATR3, SPINT2 PSIP1 2027/4885HSD11B1 2151/4885L3MBTL1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.